We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
226
STRS Ohio
Ohio
– -$970K -7,355 Closed
Manulife (Manufacturers Life Insurance)
227
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$935K -7,085 Closed
ProShare Advisors
228
ProShare Advisors
Maryland
– -$934K -7,077 Closed
VRS
229
Virginia Retirement Systems
Virginia
– -$914K -6,928 Closed
Principal Financial Group
230
Principal Financial Group
Iowa
– -$914K -6,925 Closed
SP
231
SIH Partners
Delaware
– -$882K -6,685 Closed
HT
232
Headlands Technologies
Illinois
– -$876K -6,637 Closed
PCIA
233
Prime Capital Investment Advisors
Kansas
– -$859K -6,515 Closed
Envestnet Asset Management
234
Envestnet Asset Management
Illinois
– -$838K -6,349 Closed
MIM
235
MetLife Investment Management
New Jersey
– -$835K -6,329 Closed
LPL Financial
236
LPL Financial
California
– -$820K -6,219 Closed
Blackstone Inc
237
Blackstone Inc
New York
– -$819K -6,211 Closed
SVWAG
238
Sound View Wealth Advisors Group
Georgia
– -$816K -6,189 Closed
Prudential Financial
239
Prudential Financial
New Jersey
– -$545K -6,030 Closed
KCM
240
Kennedy Capital Management
Missouri
– -$768K -5,822 Closed
Wells Fargo
241
Wells Fargo
California
– -$761K -5,772 Closed
OSAM
242
O'Shaughnessy Asset Management
Connecticut
– -$761K -5,768 Closed
Truist Financial
243
Truist Financial
North Carolina
– -$757K -5,736 Closed
QCM
244
Quantinno Capital Management
New York
– -$740K -5,606 Closed
CIA
245
Concurrent Investment Advisors
Florida
– -$733K -5,557 Closed
URS
246
Utah Retirement Systems
Utah
– -$726K -5,500 Closed
SPS
247
Susquehanna Portfolio Strategies
Pennsylvania
– -$724K -5,486 Closed
Mercer Global Advisors
248
Mercer Global Advisors
Colorado
– -$703K -5,328 Closed
CAPTRUST Financial Advisors
249
CAPTRUST Financial Advisors
North Carolina
– -$690K -5,234 Closed
CGIM
250
Cannon Global Investment Management
Florida
– -$674K -5,112 Closed
8 9
10
11 12

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.